Last reviewed · How we verify
EVEROLIMUS
At a glance
| Generic name | EVEROLIMUS |
|---|---|
| Drug class | Kinase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
Common side effects
- Hypercholesterolemia
- Stomatitis
- Elevated partial thromboplastin time
- Neutropenia
- Anemia
- Respiratory tract infection
- Hypertriglyceridemia
- Pyrexia
- Vomiting
- Anxiety, aggression or other behavioral disturbance
- Rash
- Elevated AST
Serious adverse events
- Stomatitis
- Neutropenia
- Pyrexia
- Gastroenteritis
- Anxiety, aggression or other behavioral disturbance
- Pneumonia
- Respiratory tract infection
- Elevated partial thromboplastin time
- Pneumonitis
- Hypersensitivity
Key clinical trials
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
- RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS (PHASE1)
- Esprit BTK Post-Approval Study (NA)
- A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVEROLIMUS CI brief — competitive landscape report
- EVEROLIMUS updates RSS · CI watch RSS